Active Ingredient(s): Cytarabine Liposomal, ARA-C
FDA Approved: * April 1, 1999
Pharm Company: * SKYEPHARMA
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

DepoCyt Overview

Cytarabine, also known as cytosine arabinoside (ara-C), is a chemotherapy medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma.[1] It is given by injection into a vein, under the skin, or into the cerebrospinal fluid.[1] There is a liposomal formulation for which there is tentative evidence of better outcomes in lymphoma involving the meninges.[1] ...

Read more DepoCyt Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent DepoCyt Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Cytarabine Liposomal, ARA-C
  • Injection: 10mg/ml
  • Injection, Liposomal: 10mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for DepoCyt: (1 result)

Sorted by National Drug Code
  • 57665-331 Depocyt 50 mg/5ml Intrathecal Injection, Lipid Complex by Sigma-tau Pharmaceuticals, Inc.

Other drugs which contain Cytarabine Liposomal, ARA-C or a similar ingredient: (1 result)